LM 101
Alternative Names: LM-101 - LaNova Medicines Limited; LM101Latest Information Update: 10 Jul 2024
At a glance
- Originator LaNova Medicines Limited
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; SIRPA protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Colorectal cancer; Non-Hodgkin's lymphoma; Renal cell carcinoma
Most Recent Events
- 31 May 2024 Efficacy and adverse event data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 15 Nov 2023 LaNova Medicines suspends a phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in China (IV), due to HSP622C-2022001 stability data question (NCT05615974)
- 15 Nov 2023 LaNova Medicines suspends a phase-I/II clinical trials in Solid tumours (Monotherapy, Second-line therapy or greater, Late-stage disease) in China (IV), due to HSP622C-2022001 stability data question (NCT05615974)